

## TruStain FcX™ PLUS (anti-mouse CD16/32) Antibody

<b>Catalog# / Size</b>	156603 / 50 µg 156604 / 500 µg
<b>Clone</b>	S17011E
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	CD16, CD32
<b>Isotype</b>	Rat IgG2b, κ
<b>Description</b>	CD16 is the low affinity IgG Fc receptor III (FcR III) and CD32 is FcR II. CD16/CD32 are expressed on B cells, monocytes/macrophages, NK cells, granulocytes, mast cells, and dendritic cells. The Fc receptors bind antibody-antigen immune complexes and mediate adaptive immune responses. TruStain FcX™ PLUS is specific to the common epitope of CD16/CD32. It is useful for blocking non-specific binding of immunoglobulin to the Fc receptors and is more effective than TruStain FcX™.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Purity</b>	The antibody was purified by affinity chromatography.
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Concentration</b>	0.5 mg/ml
<b>Storage &amp; Handling</b>	The CD16/32 antibody solution should be stored undiluted between 2°C and 8°C.
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	For blocking of Fc receptors in flow cytometric analysis, pre-incubate the cells with TruStain FcX™ PLUS for 5-10 minutes, on ice, at 0.25 µg per 10 <sup>6</sup> cells in a volume of 100 µl, prior to immunostaining. It is not necessary to wash the cells between the blocking and immunostaining steps.
<b>Application Notes</b>	Clone S17011E blocks both clone 93 and 2.4G2 also raised against mouse CD16/32
<b>Product Citations</b>	<ol style="list-style-type: none"> <li>Zhou J, <i>et al.</i> 2021. J Immunother Cancer. 9:. <a href="#">PubMed</a></li> <li>Driscoll J, <i>et al.</i> 2021. Curr Protoc. 1:e249. <a href="#">PubMed</a></li> <li>Fu R, <i>et al.</i> 2020. Sci Rep. 10:1455. <a href="#">PubMed</a></li> <li>Bian L, <i>et al.</i> 2022. Front Immunol. 13:938598. <a href="#">PubMed</a></li> <li>Thomas AM, <i>et al.</i> 2022. J Neuroinflammation. 19:130. <a href="#">PubMed</a></li> <li>Uzhachenko RV, <i>et al.</i> 2021. Cell Reports. 35(1):108944. <a href="#">PubMed</a></li> <li>Rodriguez-García A, <i>et al.</i> 2021. Nat Commun. 12:877. <a href="#">PubMed</a></li> <li>Toomer G, <i>et al.</i> 2022. Viruses. 14:. <a href="#">PubMed</a></li> <li>Oliva Chávez AS, <i>et al.</i> 2021. Nat Commun. 12:3696. <a href="#">PubMed</a></li> <li>Music A, <i>et al.</i> 2022. Front Cell Dev Biol. 10:987148. <a href="#">PubMed</a></li> <li>Kienzl M, <i>et al.</i> 2020. Oncoimmunology. 9:1776059. <a href="#">PubMed</a></li> <li>Westphal A, <i>et al.</i> 2017. J Exp Med. 214:227. <a href="#">PubMed</a></li> <li>Geng T, <i>et al.</i> 2022. Methods Mol Biol. 2585:71. <a href="#">PubMed</a></li> <li>Chen X, <i>et al.</i> 2022. J Appl Oral Sci. 30:e20220316. <a href="#">PubMed</a></li> <li>Ikeda S, <i>et al.</i> 2022. Sci Rep. 12:11564. <a href="#">PubMed</a></li> <li>Thinard R, <i>et al.</i> 2022. Pharmaceutics. 14:. <a href="#">PubMed</a></li> <li>So EY, <i>et al.</i> 2021. Am J Physiol Cell Physiol. 321:C569. <a href="#">PubMed</a></li> <li>Wang JC, <i>et al.</i> 2022. Elife. 11:. <a href="#">PubMed</a></li> <li>Zeng W, <i>et al.</i> 2021. STAR Protocols. 2(1):100361. <a href="#">PubMed</a></li> <li>Oguri Y, <i>et al.</i> 2020. Cell. 182(3):563-577.e20. <a href="#">PubMed</a></li> <li>Dong L, <i>et al.</i> 2022. Cells. 11:. <a href="#">PubMed</a></li> <li>Pathania AS, <i>et al.</i> 2022. Mol Ther Oncolytics. 25:308. <a href="#">PubMed</a></li> </ol>

23. Ejima R, *et al.* 2021. *Nutrients*. 13: PubMed
24. Guo S, *et al.* 2021. *Sci Rep*. 11:23745. PubMed
25. Gomez S, *et al.* 2022. *J Immunother Cancer*. 10: PubMed
26. Grubišić V, *et al.* 2020. *Cell Rep*. 32:108100. PubMed
27. Galani IE, *et al.* 2022. *STAR Protoc*. 3:101151. PubMed
28. Olson B, *et al.* 2021. *Brain Behav Immun*. 97:102. PubMed
29. Chakraborty M, *et al.* 2021. *Cell Reports*. 34(2):108609. PubMed
30. Montel-Hagen A, *et al.* 2022. *Curr Protoc*. 2:e403. PubMed
31. Chen AF, *et al.* 2022. *Nat Methods*. 19:547. PubMed
32. Kos S, *et al.* 2019. *PLoS One*. 14:e0217762. PubMed
33. Rocha-Resende C, *et al.* 2020. *JCI Insight*. 5:00. PubMed
34. Li N, *et al.* 2022. *Nat Commun*. 13:7281. PubMed
35. Chen S, *et al.* 2022. *iScience*. 25:105176. PubMed
36. Oya Y, *et al.* 2021. *Front Immunol*. 12:779709. PubMed
37. Hobbs BE, *et al.* 2021. *Pathogens*. 10: PubMed
38. Alhudaithi SS, *et al.* 2020. *Mol Pharm*. 17:4691. PubMed
39. Fan ZP, *et al.* 2021. *Front Immunol*. 12:743354. PubMed
40. Phan TS, *et al.* 2021. *Sci Adv*. 7: PubMed
41. Casselli T, *et al.* 2021. *PLoS Pathog*. 17:e1009256. PubMed
42. Jiang Y, *et al.* 2021. *Nat Commun*. 12:742. PubMed
43. Madsen CS, *et al.* 2022. *Commun Biol*. 5:888. PubMed
44. Liu Q, *et al.* 2021. *Adv Mater*. 33:e2102852. PubMed
45. Beyer AI, *et al.* 2017. *Stem Cells Dev*. 26:102. PubMed
46. Van Winkle JA, *et al.* 2020. *J Virol*. 94: PubMed
47. Wang Y, *et al.* 2021. *Nature*. 599:308. PubMed
48. Wang X, *et al.* 2021. *Sci Transl Med*. 13: PubMed
49. Gardner A, *et al.* 2022. *J Immunother Cancer*. 10: PubMed
50. Xu L, *et al.* 2022. *Front Immunol*. 13:841141. PubMed
51. Matsuda A, *et al.* 2020. *J Appl Toxicol*. 40:706. PubMed
52. Badgujar DC, *et al.* 2020. *PLoS Pathog*. 16:e1009016. PubMed
53. Celias DP, *et al.* 2022. *STAR Protoc*. 3:101464. PubMed

**RRID** AB\_2783137 (BioLegend Cat. No. 156603)  
 AB\_2783138 (BioLegend Cat. No. 156604)

## Antigen Details

---

<b>Structure</b>	Ig superfamily, 40-60 kD
<b>Distribution</b>	B cells, monocyte/macrophages, NK cells, neutrophils, mast cells, dendritic cells
<b>Ligand/Receptor</b>	IgG
<b>Cell Type</b>	B cells, Dendritic cells, Macrophages, Mast cells, Monocytes, Neutrophils, NK cells
<b>Biology Area</b>	Immunology
<b>Molecular Family</b>	CD Molecules, Fc Receptors
<b>Gene ID</b>	<a href="#">14130</a> <a href="#">14131</a>

## Related Protocols

---

[Cell Surface Flow Cytometry Staining Protocol](#)


## Other Formats

---

TruStain FcX™ PLUS (anti-mouse CD16/32), APC/Cyanine7 anti-mouse CD16/32, PE/Cyanine7 anti-mouse CD16/32, PE anti-mouse CD16/32, APC anti-mouse CD16/32, FITC anti-mouse CD16/32 Antibody, PE/Dazzle™ 594 anti-mouse CD16/32 Antibody, PerCP/Cyanine5.5 anti-mouse CD16/32 Antibody, PE/Cyanine5 anti-mouse CD16/32, Alexa Fluor® 700 anti-mouse CD16/32, APC/Fire™ 750 anti-mouse CD16/32

## Product Data

---



BALB/c splenocytes were incubated with TruStain FcX™ PLUS (clone S17011E, 0.25µg/10<sup>6</sup> cells, filled histogram) or TruStain FcX™ (clone 93, 1µg/10<sup>6</sup> cells, red line histogram) to block the Fc receptors, or were left untreated (black line histogram); then stained with CD90.2 (Thy-1.2, clone 53-2.1) FITC. Note the high background in the untreated cells and the bigger reduction in the background staining when the cells were incubated with TruStain FcX™ Plus compared to TruStain FcX™.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
 Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587